FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2954149174> ?p ?o ?g. }

• W2954149174 endingPage "e0217014" @default.
• W2954149174 startingPage "e0217014" @default.
• W2954149174 abstract "The implementation of antiretroviral (ARV) therapy caused a significant decrease in HIV-associated mortality worldwide. Nevertheless, mortality is still high among people living with HIV/AIDS and tuberculosis (TB). ARV-naïve HIV patients coinfected with tuberculosis (TB) have more options to treat both diseases concomitantly. Nevertheless, some TB-HIV patients undertaking ARVs (ARV-experienced) are already failing the first line efavirenz-based regimen and seem to display different response to second line ARV therapy and exhibit other predictors of mortality.We performed a retrospective cohort study including 273 patients diagnosed with TB-HIV and treated at a referral center in Rio de Janeiro, Brazil, between 2008 and 2016. Multivariate analysis and Cox regression models were used to evaluate the effectiveness of ARV therapy regimens (viral load [VL] <80 copies from the 4th to 10th months after TB therapy introduction) and to identify predictors of early mortality (100 days after TB therapy initiation) considering ARV-naïve and ARV-experienced patients adjusting for sociodemographic, clinical and therapeutic covariates.Survival analysis included 273 patients, out of whom 154 (56.4%) were ARV-naïve and 119 (43.6%) were ARV-experienced. Seven deaths occurred within 6 months of anti-TB treatment, 4 in ARV-naïve and 3 in ARV-experienced patients. Multivariate analysis revealed that in ARV-naïve patients, the chance of death was substantially higher in patients who developed immune reconstitution inflammatory syndrome during the study follow up (HR = 40.6, p<0.01). For ARV-experienced patients, similar analyses failed to identify factors significantly associated with mortality. Variables independently associated with treatment failure for the ARV-naïve group were previous TB (adjusted OR [aOR] = 6.1 p = 0.03) and alcohol abuse (aOR = 3.7 p = 0.01). For ARV-experienced patients, a ritonavir boosted. Protease Inhibitor-based regimen resulted in a 2.6 times higher risk of treatment failure compared to the use of efavirenz based ARV regimens (p = 0.03) and High baseline HIV VL (p = 0.03) were predictors of treatment failure.Risk factors for mortality and ARV failure were different for ARV-naïve and ARV-experienced patients. The latter patient group should be targeted for trials with less toxic and rifampicin-compatible drugs to improve TB-HIV treatment outcomes and prevent death." @default.
• W2954149174 created "2019-07-12" @default.
• W2954149174 creator A5013968607 @default.
• W2954149174 creator A5020812138 @default.
• W2954149174 creator A5070116548 @default.
• W2954149174 creator A5070138800 @default.
• W2954149174 creator A5080892193 @default.
• W2954149174 creator A5082335247 @default.
• W2954149174 date "2019-06-06" @default.
• W2954149174 modified "2023-09-26" @default.
• W2954149174 title "Predictors of early mortality and effectiveness of antiretroviral therapy in TB-HIV patients from Brazil" @default.
• W2954149174 cites W1964622370 @default.
• W2954149174 cites W1985903363 @default.
• W2954149174 cites W1994109358 @default.
• W2954149174 cites W2008544755 @default.
• W2954149174 cites W2014140728 @default.
• W2954149174 cites W2064500065 @default.
• W2954149174 cites W2069557078 @default.
• W2954149174 cites W2076838573 @default.
• W2954149174 cites W2079154234 @default.
• W2954149174 cites W2101952047 @default.
• W2954149174 cites W2120074558 @default.
• W2954149174 cites W2122693013 @default.
• W2954149174 cites W2151102304 @default.
• W2954149174 cites W2154962788 @default.
• W2954149174 cites W2160104000 @default.
• W2954149174 cites W2166002453 @default.
• W2954149174 cites W2753920621 @default.
• W2954149174 cites W2773346955 @default.
• W2954149174 doi "https://doi.org/10.1371/journal.pone.0217014" @default.
• W2954149174 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6553696" @default.
• W2954149174 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31170171" @default.
• W2954149174 hasPublicationYear "2019" @default.
• W2954149174 type Work @default.
• W2954149174 sameAs 2954149174 @default.
• W2954149174 citedByCount "11" @default.
• W2954149174 countsByYear W29541491742019 @default.
• W2954149174 countsByYear W29541491742020 @default.
• W2954149174 countsByYear W29541491742021 @default.
• W2954149174 countsByYear W29541491742022 @default.
• W2954149174 countsByYear W29541491742023 @default.
• W2954149174 crossrefType "journal-article" @default.
• W2954149174 hasAuthorship W2954149174A5013968607 @default.
• W2954149174 hasAuthorship W2954149174A5020812138 @default.
• W2954149174 hasAuthorship W2954149174A5070116548 @default.
• W2954149174 hasAuthorship W2954149174A5070138800 @default.
• W2954149174 hasAuthorship W2954149174A5080892193 @default.
• W2954149174 hasAuthorship W2954149174A5082335247 @default.
• W2954149174 hasBestOaLocation W29541491741 @default.
• W2954149174 hasConcept C126322002 @default.
• W2954149174 hasConcept C142462285 @default.
• W2954149174 hasConcept C142724271 @default.
• W2954149174 hasConcept C167135981 @default.
• W2954149174 hasConcept C203014093 @default.
• W2954149174 hasConcept C2776135927 @default.
• W2954149174 hasConcept C2777813720 @default.
• W2954149174 hasConcept C2779778235 @default.
• W2954149174 hasConcept C2781069245 @default.
• W2954149174 hasConcept C2781413609 @default.
• W2954149174 hasConcept C2781432083 @default.
• W2954149174 hasConcept C2909923361 @default.
• W2954149174 hasConcept C2993143319 @default.
• W2954149174 hasConcept C3013748606 @default.
• W2954149174 hasConcept C38180746 @default.
• W2954149174 hasConcept C50382708 @default.
• W2954149174 hasConcept C512399662 @default.
• W2954149174 hasConcept C71924100 @default.
• W2954149174 hasConcept C72563966 @default.
• W2954149174 hasConceptScore W2954149174C126322002 @default.
• W2954149174 hasConceptScore W2954149174C142462285 @default.
• W2954149174 hasConceptScore W2954149174C142724271 @default.
• W2954149174 hasConceptScore W2954149174C167135981 @default.
• W2954149174 hasConceptScore W2954149174C203014093 @default.
• W2954149174 hasConceptScore W2954149174C2776135927 @default.
• W2954149174 hasConceptScore W2954149174C2777813720 @default.
• W2954149174 hasConceptScore W2954149174C2779778235 @default.
• W2954149174 hasConceptScore W2954149174C2781069245 @default.
• W2954149174 hasConceptScore W2954149174C2781413609 @default.
• W2954149174 hasConceptScore W2954149174C2781432083 @default.
• W2954149174 hasConceptScore W2954149174C2909923361 @default.
• W2954149174 hasConceptScore W2954149174C2993143319 @default.
• W2954149174 hasConceptScore W2954149174C3013748606 @default.
• W2954149174 hasConceptScore W2954149174C38180746 @default.
• W2954149174 hasConceptScore W2954149174C50382708 @default.
• W2954149174 hasConceptScore W2954149174C512399662 @default.
• W2954149174 hasConceptScore W2954149174C71924100 @default.
• W2954149174 hasConceptScore W2954149174C72563966 @default.
• W2954149174 hasFunder F4320323916 @default.
• W2954149174 hasIssue "6" @default.
• W2954149174 hasLocation W29541491741 @default.
• W2954149174 hasLocation W29541491742 @default.
• W2954149174 hasLocation W29541491743 @default.
• W2954149174 hasLocation W29541491744 @default.
• W2954149174 hasLocation W29541491745 @default.
• W2954149174 hasLocation W29541491746 @default.
• W2954149174 hasLocation W29541491747 @default.
• W2954149174 hasOpenAccess W2954149174 @default.
• W2954149174 hasPrimaryLocation W29541491741 @default.

• next